Global Campath/MabCampath Market Research Report

Key Questions Answered

• What are market estimates and forecasts; which of Campath/MabCampath markets are doing well and which are not?
• What is the competitive landscape; How companies like Genzyme Corporation, Glaxosmithkline Plc and F. Hoffmann-La Roche Ltd. doing in Campath/MabCampath?

 

What makes our report unique?

• This report provides market sizing and forecast for the Campath/MabCampath market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
• The report provides deep dive competitive landscape covering the top players such as Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).
• The reports provides benchmarking insight on the top players Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).
• The report provide competitive intelligence on Genzyme Corporation, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd. and Teva Pharmaceuticals, Inc (cephalon).

 

Audience for this report

• Global Campath/MabCampath companies
• Manufacturing Companies
• Traders, distributors, and suppliers
• Governmental and research organizations
• Associations and industry bodies
• Technology providers

 

Top developments

• GSK and Genmab (Denmark) reported results of concluded pivotal trial of Arzerra (ofatumumab) for the treatment of CLL patient refractory to fludarabine and alemtuzumab
• GSK and Genmab (Denmark) obtained European Commission (EC) grant for Arzerra.
• Roche obtained U.S. FDA approval for Rituxan in combination with fludarabine and cyclophosphamide (FC) for the treatment of CD20-positive chronic lymphocytic leukemia
• Genzyme declared data from CAM314 randomized phase III clinical trial of Campath (alemtuzumab) along with Fludara (fludarabine phosphate) compared to only Fludara for refractory chronic lymphocytic leukemia.
• Roche stated pivotal phase III CLL8 three-year follow up results for untreated chronic lymphocytic leukemia.
• GSK and Genmab (Denmark) obtained accelerated U.S. FDA approval for Arzerra
• Roche received European Commission approval for rituximab (MabThera) for the treatment of relapsed or refractory chronic lymphocytic leukemia.
• Genentech and Biogen Idec submitted two Biologics License Applications (sBLAs) to the U.S. FDA for Rituxan plus standard chemotherapy
• Genzyme acquired marketing rights of Campath from Bayer HealthCare.
• The European Medicines Agency (EMEA) approved the Marketing Authorization Application (MAA) of GSK and Genmab for Arzerra

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :Global Campath/MabCampath Market Research Report

* Enter the text from the image to the text box :